New Ask Claude or ChatGPT about any stock, using Bullpen. Bullpen in Claude or ChatGPT. 7 days free

Friday, November 13, 2026

Back to the front page

From X

Fajasy on X

Elmet $ELMT, which turns tungsten into parts for U.S. missiles and jets, has raised $325.4M in 2026, including its April IPO and $200M from the U.S. Department of War (DoW), and ~$81M of cash was left after it paid for stakes in two tungsten miners in October. $124.7M bought 4.99% of Masan High-Tech Materials (UPCoM: MSR), $ELMT's longtime Vietnamese supplier, and $24.7M bought 3.5M shares, plus warrants, of Blue Moon Metals $BMM, owner of the Springer tungsten mine in Nevada. Operations used another $60.7M through October 2 ($53.1M in Q3 alone), mostly to build inventory, which more than doubled to $152.8M from $69.7M as of December 31. Counting the $124.7M set aside for Masan as cash, net cash went from the $60.5M I calculated after the DoW deal in my September 17 update to ~$0 as of October 2. At $21.99, $ELMT is 4.4% below the $23 I used in September, but its EV rose to ~$811M from $784M, mostly because of the Q3 inventory build. The DoW's remaining $250M can't arrive before March 2027, comes in at most $50M per six-month window, and each draw has to name its use and meet the DoW's conditions. $ELMT's plan for the DoW money still has more than $290M to fund: (1) $165M+ to upgrade and expand its three U.S. plants, (2) $75M for its 70% of the joint venture restarting Springer's processing plant, and (3) a $50M advance to Blue Moon against future Springer tungsten. So until the first DoW draw lands, any spending on Springer, the plant upgrades, or more inventory comes from the ~$81M of cash, $18.1M of unused credit lines, and whatever cash the business generates.

QXO Inc Earnings Update: Q3 2026

QXO's Q3 sales rose 79% to $4.9 billion after TopBuild and Kodiak acquisitions, while acquisition debt lifted interest expense to $163…

IEH Corporation: Research Note

IEH Corporation posted Q2 revenue growth of 51% to $10.7 million and a record $56 million backlog, led by defense and medical demand.

Qure Anniversary Update

UniQure’s Huntington’s disease BLA has a May 1, 2027 priority-review date, with an FDA advisory committee expected in late first quarter.

Big Short: Fidelity & Guaranty

F&G’s main insurer held $66.5 billion of assets against $1.38 billion of statutory capital, while private credit, reinsurance dependence…

Top Rebound Stocks for Nov’26

Texas Pacific Land's 50% selloff reflects faded data-center expectations, while its Permian royalty business generated $498 million of 2025…

ASML ($ASML) Deep Dive

ASML monopolizes EUV lithography, a critical tool for leading-edge chips, with production capacity stretched through 2028 and customer…

Publications we follow

Every publication on this site, hand-picked.

130 publications

Newsletters 110

X accounts we follow

Every account on this site, hand-picked.

91 accounts

Investor letters we follow

376 firms

Sectors

Ordered by how often our editor reaches for them.